化合物PT-2385 T7848

Product Introduction
Bioactivity


英文名: PT-2385

描述: PT-2385 是一种选择性HIF-2α抑制剂，Ki< 50 nM。

动物实验: Animal Model: SCID/beige mice with the 786-O and A498 RCC cell lines. Dosage: 30 or 100 mg/kg. Administration: Oral gavage; twice daily [2]

体外活性: PT-2385是一种针对HIF-2的选择性拮抗剂，对HIF-1α无活性[1]。

体内活性: PT-2385 inhibits expression of HIF-2α regulated genes in a dose dependent manner in vivo. Tumor is regressed with PT-2385 (3 and 10 mg/kg, p.o., b.i.d. dose) in 786-O xenograft. PT-2385 (1,3 and 10 mg/kg) also inhibits tumor-derived VEGFA protein levels. PT-2385 (10 mg/kg) treatment reduces proliferation (Ki67) and angiogenesis (CD-31) [1]. PT-2385 (30 or 100 mg/kg; oral gavage; twice daily) result in a rapid, dose-dependent tumor regression [2].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 55 mg/mL (143.48 mM)


关键字: Inhibitor | PT2385 | inhibit | PT-2385 | Hypoxia-inducible factors | HIF/HIF Prolyl-Hydroxylase | PT 2385 | HIF-PH | HIFs

相关产品: Citric acid trilithium salt tetrahydrate | Amifostine trihydrate | HIF-2α-IN-2 | Oroxylin A | E3330 | PX-478 | IOX2 | HIF-1α-IN-2 hydrochloride | TM6089 | MK-8617

相关库: Drug Repurposing Compound Library | Anti-Cancer Drug Library | Bioactive Compounds Library Max | Inhibitor Library | Anti-Cancer Clinical Compound Library | Anti-Cancer Active Compound Library | Metabolism Compound Library | Anti-Pancreatic Cancer Compound Library | NO PAINS Compound Library | Bioactive Compound Library

化合物PT-2385 T7848信息由TargetMol中国为您提供，如您想了解更多关于化合物PT-2385 T7848报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途